150 related articles for article (PubMed ID: 34259197)
21. A Phase II, Randomized, Open-Label Study of Neoadjuvant Degarelix versus LHRH Agonist in Prostate Cancer Patients Prior to Radical Prostatectomy.
Sayyid RK; Evans A; Hersey K; Maloni R; Hurtado-Coll A; Kulkarni G; Finelli A; Zlotta AR; Hamilton R; Gleave M; Fleshner NE
Clin Cancer Res; 2017 Apr; 23(8):1974-1980. PubMed ID: 27756786
[No Abstract] [Full Text] [Related]
22. Recovery of serum testosterone, LH and FSH levels following neoadjuvant hormone cytoreduction and radical radiotherapy in localized prostate cancer.
Shahidi M; Norman AR; Gadd J; Huddart RA; Horwich A; Dearnaley DP
Clin Oncol (R Coll Radiol); 2001; 13(4):291-5. PubMed ID: 11554629
[TBL] [Abstract][Full Text] [Related]
23. Effects of chronic testosterone administration in normal men: safety and efficacy of high dosage testosterone and parallel dose-dependent suppression of luteinizing hormone, follicle-stimulating hormone, and sperm production.
Matsumoto AM
J Clin Endocrinol Metab; 1990 Jan; 70(1):282-7. PubMed ID: 2104626
[TBL] [Abstract][Full Text] [Related]
24. Effect of mifepristone (RU486) on the pituitary response to gonadotrophin releasing hormone in women.
Kazem R; Messinis LE; Fowler P; Groome NP; Knight PG; Templeton AA
Hum Reprod; 1996 Dec; 11(12):2585-90. PubMed ID: 9021355
[TBL] [Abstract][Full Text] [Related]
25. Differential Impact of Gonadotropin-releasing Hormone Antagonist Versus Agonist on Clinical Safety and Oncologic Outcomes on Patients with Metastatic Prostate Cancer: A Meta-analysis of Randomized Controlled Trials.
Abufaraj M; Iwata T; Kimura S; Haddad A; Al-Ani H; Abusubaih L; Moschini M; Briganti A; Karakiewicz PI; Shariat SF
Eur Urol; 2021 Jan; 79(1):44-53. PubMed ID: 32605859
[TBL] [Abstract][Full Text] [Related]
26. Effect of gonadotropin-releasing hormone antagonists on serum follicle-stimulating hormone and luteinizing hormone under conditions of singular follicle-stimulating hormone secretion.
Schwartz NB; Rivier C; Rivier J; Vale WW
Biol Reprod; 1985 Mar; 32(2):391-8. PubMed ID: 3921074
[TBL] [Abstract][Full Text] [Related]
27. Long-term administration of gonadotropin-releasing hormone agonist and dexamethasone: assessment of the adrenal role in ovarian dysfunction.
Cedars MI; Steingold KA; de Ziegler D; Lapolt PS; Chang RJ; Judd HL
Fertil Steril; 1992 Mar; 57(3):495-500. PubMed ID: 1531463
[TBL] [Abstract][Full Text] [Related]
28. Follicle-Stimulating Hormone Exacerbates Cardiovascular Disease in the Presence of Low or Castrate Testosterone Levels.
Duivenvoorden WCM; Margel D; Subramony Gayathri V; Duceppe E; Yousef S; Naeim M; Khajehei M; Hopmans S; Popovic S; Ber Y; Heels-Ansdell D; Devereaux PJ; Pinthus JH
JACC Basic Transl Sci; 2024 Mar; 9(3):364-379. PubMed ID: 38559622
[TBL] [Abstract][Full Text] [Related]
29. Gonadotropin-releasing hormone, estradiol, and inhibin regulation of follicle-stimulating hormone and luteinizing hormone surges: implications for follicle emergence and selection in heifers.
Haughian JM; Ginther OJ; Diaz FJ; Wiltbank MC
Biol Reprod; 2013 Jun; 88(6):165. PubMed ID: 23658431
[TBL] [Abstract][Full Text] [Related]
30. Developments in the control of testicular function.
Swerdloff RS; Wang C; Bhasin S
Baillieres Clin Endocrinol Metab; 1992 Apr; 6(2):451-83. PubMed ID: 1377467
[TBL] [Abstract][Full Text] [Related]
31. Androgen selectively stimulates follicle-stimulating hormone-beta mRNA levels after gonadotropin-releasing hormone antagonist administration.
Wierman ME; Wang C
Biol Reprod; 1990 Mar; 42(3):563-71. PubMed ID: 2111188
[TBL] [Abstract][Full Text] [Related]
32. A gonadotropin-releasing hormone antagonist reduces serum adrenal androgen levels in prostate cancer patients.
Miyazawa Y; Sekine Y; Syuto T; Nomura M; Koike H; Matsui H; Shibata Y; Ito K; Suzuki K
BMC Urol; 2017 Aug; 17(1):70. PubMed ID: 28851333
[TBL] [Abstract][Full Text] [Related]
33. Investigative clinical study on prostate cancer part VIII: prolactin hormone and the pituitary-testicular-prostate axis at the time of initial diagnosis and subsequent cluster selection of the patient population after radical prostatectomy.
Porcaro AB; Ghimenton C; Petrozziello A; Migliorini F; Romano M; Sava T; Caruso B; Cocco C; Antoniolli SZ; Lacola V; Rubilotta E; Monaco C; Comunale L
Anticancer Res; 2012 Apr; 32(4):1499-506. PubMed ID: 22493393
[TBL] [Abstract][Full Text] [Related]
34. Follicle-stimulating hormone (FSH) escape during chronic gonadotropin-releasing hormone (GnRH) agonist and testosterone treatment.
Bhasin S; Berman N; Swerdloff RS
J Androl; 1994; 15(5):386-91. PubMed ID: 7860418
[TBL] [Abstract][Full Text] [Related]
35. [Change of serum adrenal androgens in prostatic cancer patients after bilateral orchidectomy or LHRH agonist treatment].
Oka H; Negoro H; Sugino Y; Iwamura H; Moroi S; Kawakita M
Hinyokika Kiyo; 2003 Sep; 49(9):521-5. PubMed ID: 14598689
[TBL] [Abstract][Full Text] [Related]
36. The effect of pulsatile gonadotropin-releasing hormone and estradiol administration on luteinizing hormone and follicle-stimulating hormone concentrations in pituitary stalk-sectioned ovariectomized pony mares.
Porter MB; Cleaver BD; Peltier M; Robinson G; Sharp DC
Domest Anim Endocrinol; 1997 Sep; 14(5):275-85. PubMed ID: 9347248
[TBL] [Abstract][Full Text] [Related]
37. Effect of cryosurgery of the prostate in serum gonadotropin levels in prostatic cancer.
Washida H; Jinno H; Fushimi N; Watanabe H
Cryobiology; 1982 Jun; 19(3):237-41. PubMed ID: 6809427
[TBL] [Abstract][Full Text] [Related]
38. Lamprey gonadotropin-releasing hormone-III selectively releases follicle stimulating hormone in the bovine.
Dees WL; Dearth RK; Hooper RN; Brinsko SP; Romano JE; Rahe H; Yu WH; McCann SM
Domest Anim Endocrinol; 2001 May; 20(4):279-88. PubMed ID: 11518621
[TBL] [Abstract][Full Text] [Related]
39. Long-term treatment outcomes of intermittent androgen deprivation therapy for relapsed prostate cancer after radical prostatectomy.
Maru S; Uchino H; Osawa T; Chiba S; Mouri G; Sazawa A
PLoS One; 2018; 13(5):e0197252. PubMed ID: 29795595
[TBL] [Abstract][Full Text] [Related]
40. Effects of gonadotropin-releasing hormone on bioactivity of follicle-stimulating hormone (FSH) and microstructure of FSH, luteinizing hormone and sex hormone-binding globulin in a testosterone-based contraceptive trial: evaluation of responders and non-responders.
Simoni M; Peters J; Behre HM; Kliesch S; Leifke E; Nieschlag E
Eur J Endocrinol; 1996 Oct; 135(4):433-9. PubMed ID: 8921825
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
